Recent 8-K filings for COSM
Highest-materiality recent filing
Cosmos Health secures up to $300M convertible note facility for Ethereum treasury strategy
- Up to $300M in 9% senior secured convertible notes; initial $8M close on Aug 6, 2025.
- 72.5% of net proceeds to be used to acquire Ethereum (ETH) as a digital asset treasury reserve.
-
Cosmos Health Q1 revenue +31% to $17.93M; net loss widens to $2.81M
Q1 revenue $17.93M, up 31% YoY from $13.71M; adjusted revenue $18.40M (+34.2%).
-
Revenue $65.3M (+20% YoY); gross profit $7.9M (+83%); gross margin 12.1% (+418 bps).
-
Cosmos Health receives Nasdaq bid-price deficiency notice; 180-day cure period
Received non-compliance letter on Dec 11, 2025 for bid price below $1.00 for 30 consecutive business days.
-
Cosmos Health Q3 2025 revenue $17.1M (+38% YoY), record gross margin 15.2%, cash jumps to $4.63M
Q3 2025 revenue $17.11M (up 38% YoY); gross profit $2.60M (+116%), gross margin 15.21% (vs 9.72%).
-
Cosmos Health regains compliance with Nasdaq minimum bid price requirement
Received Nasdaq notice on Oct 15, 2025 confirming compliance with Minimum Bid Price Rule.
-
Elected six directors: Siokas, Demetriades, Hoidas, Aslidis, Bhutawala, Karkantzos with majority votes.
-
Cosmos Health CEO letter details $300M digital asset facility, H1 revenue up 11.7%, 2027 guidance
Secured $300M senior secured convertible note; 72.5% net proceeds to digital treasury (ETH, BTC, SOL).
-
Cosmos Health closes $8M senior secured convertible note with 9% OID, conversion at $1.05
Issued $8M original principal 9% senior secured convertible note to institutional investor on August 7, 2025.
-
Cosmos Health secures up to $300M convertible note facility for Ethereum treasury strategy
Up to $300M in 9% senior secured convertible notes; initial $8M close on Aug 6, 2025.
-
Cosmos Health enters exclusive license for two cancer-treatment patents; up to EUR 7.5M buy-out
Exclusive worldwide license for two patents (filed 2016, 2017) to treat cancer; commercialize via R&D and trials.
-
Cosmos Health receives Nasdaq bid price deficiency notice; 180-day cure period
Nasdaq notified Cosmos Health of non-compliance with minimum $1.00 bid price rule as of Nov 6, 2024.
-
Cosmos Health enters warrant exchange agreement, issues 9.7M new warrants at $0.95
Holder exercised 4,874,126 December 2023 warrants at reduced price of $0.8701 per share.
-
Cosmos Health receives additional Nasdaq delinquency notice for late 10-K and 10-Q filings
Received Nasdaq delinquency letter on May 21, 2024 for failure to timely file Q1 2024 Form 10-Q and remaining delinquent on 2023 Form 10-K.
-
Cosmos Health dismisses KPMG amid dispute over inventory transactions; appoints RBSM
KPMG dismissed on April 26, 2024 after failing to complete 2023 audit timely; cites unresolved inventory concerns.
-
Cosmos Health dismisses KPMG, hires RBSM; KPMG flags possible illegal act, company disagrees
Dismissed KPMG as auditor immediately on April 26, 2024; KPMG unable to complete 2023 audit on time.
-
Cosmos Health dismisses KPMG as auditor; KPMG unable to complete FY2023 audit on time
Dismissed KPMG effective April 26, 2024; Audit Committee unanimous vote.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.65 · Most common event other_material